Curis (CRIS) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Curis (CRIS) PT Lowered to $3 at Baird
November 1, 2018 1:58 PM EDTBaird analyst Brian Skorney lowered the price target on Curis (NASDAQ: CRIS) to $3.00 (from $6.00) while maintaining a Outperform rating after management outlined plans to refocus efforts toward the three clinical program.
"Pivoting development of CA-170 away from PD-1/L1 eligible patients and... More
